外泌体生物标志物与肿瘤发生发展的研究进展

doi:10.6040/j.issn.1671-7554.0.2018.1026

摘要/Abstract

摘要： 外泌体是一种直径为50~200 nm的双层脂质包裹体结构,可携带多种蛋白质、脂质及核酸,在细胞间信息传递中发挥重要作用,其作为一种新型生物标志物已成为近年临床关注的热点。研究发现,肿瘤细胞分泌的外泌体在肿瘤免疫、血管生成、肿瘤微环境调节等肿瘤发生发展过程中均扮演重要角色,并有可能成为药物的天然载体用于肿瘤治疗。随着蛋白组学、基因组学等技术的发展,外泌体的生物学特点和功能研究进一步深入,外泌体提取及检测技术不断进步,为肿瘤临床诊断与治疗提供了新的思路和契机。

关键词: 外泌体, 肿瘤, 生物标志物, 诊断, 非编码RNA, 耐药

Abstract: Exosomes, a double-layer lipid inclusion with a diameter of 50-200 nm, can carry a variety of proteins, lipids and nucleic acids, playing an important role in intercellular information transfer. As a novel biomarker, exosomes has become a hot topic in clinical reasearches in recent years. Studies have found that exosomes secreted by tumor cells play an important role in the development of tumors such as tumor immunity, angiogenesis, and tumor microenvironment 山东大学学报 (医学版)56卷10期 -王传新.外泌体生物标志物与肿瘤发生发展的研究进展 \=-regulation, and may become the natural carrier of drugs for tumor treatment. With the development of proteomics, genomics and other technologies, the research on the biological characteristics and functions of exosomes has been further deepened, and the extraction and detection of exosomes have been continuously improved, providing new ideas and opportunities for the clinical diagnosis and treatment of tumors.

Key words: Exosome, Tumor, Biomarker, Diagnosis, Non-coding RNA, Drug resistance

中图分类号:

R574

王传新. 外泌体生物标志物与肿瘤发生发展的研究进展[J]. 山东大学学报 (医学版), 2018, 56(10): 18-23.

WANG Chuanxin. Research progress of exosomes biomarkers in tumor development[J]. Journal of Shandong University (Health Sciences), 2018, 56(10): 18-23.

参考文献

[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018[J]. CA Cancer J Clin, 2018, 68(1): 7-30.
[2] Siegel RL, Jemal A, Wender RC, et al. An assessment of progress in cancer control[J]. CA Cancer J Clin, 2018. doi: 10.3322/caac.21460.
[3] Mause S, FandWeber C. Microparticles: protagonists of a novel communication network for intercellular information exchange[J]. Circ Res, 2010, 107(9): 1047-1057.
[4] Szajnik M, Derbis M, Lach M, et al. Exosomes in plasma of patients with ovarian carcinoma: potential biomarkers of tumor progression and response to therapy[J]. Gynecol Obstet, 2013(Suppl 4): 3. doi: 10.4172/2161-0932.S4-003.
[5] Gobbo J, Marcion G, Cordonnier M, et al. Restoring anticancer immune response by targeting tumor-derived exosomes with a hsp70 peptide aptamer[J]. J Natl Cancer Inst, 2015, 108(3): djv330.
[6] Rakoczi E, Perge B, Vegh E, et al. Evaluation of the immunogenicity of the 13-valent conjugated pneumococcal vaccine in rheumatoid arthritis patients treated with etanercept[J]. Joint Bone Spine, 2016, 83(6): 675-679.
[7] Yu DD, Wu Y, Shen HY, et al. Exosomes in development, metastasis and drug resistance of breast cancer[J]. Cancer Sci, 2015, 106(8): 959-964.
[8] Maia J, Caja S, Strano Moraes MC, et al. Exosome-based cell-cell communication in the tumor microenvironment[J]. Front Cell Dev Biol, 2018, 6: 18. doi: 10.3389/fcell.2018.00018.
[9] Johnstone RM, Adam M, Hammond JR, et al. Vesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles(exosomes)[J]. J Biol Chem, 1987, 262(19): 9412-9420.
[10] EL Andaloussi S, Mager I, Breakefield XO, et al. Extracellular vesicles: biology and emerging therapeutic opportunities[J]. Nat Rev Drug Discov, 2013, 12(5): 347-357.
[11] Rider MA, Hurwitz S, Meckes DG Jr. ExtraPEG: a polyethylene glycol-based method for enrichment of extracellular vesicles[J]. Sci Rep, 2016, 6: 23978. doi: 10.1038/srep23978.
[12] Zaborowski MP, Balaj L, Breakefield XO, et al. Extracellular vesicles: composition, biological relevance, and methods of study[J]. Bioscience, 2015, 65(8): 783-797.
[13] Chen G, Huang AC, Zhang W, et al. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response[J]. Nature, 2018, 560(7718): 382-386.
[14] Yuyama K, Sun H, Mitsutake S, et al. Sphingolipid-modulated exosome secretion promotes clearance of amyloid-beta by microglia[J]. J Biol Chem, 2012, 287(14): 10977-10989.
[15] Yan W, Wu X, Zhou W, et al. Cancer-cell-secreted exosomal miR-105 promotes tumour growth through the MYC-dependent metabolic reprogramming of stromal cells[J]. Nat Cell Biol, 2018, 20(5): 597-609.
[16] Kalra H, Adda CG, Liem M, et al. Comparative proteomics evaluation of plasma exosome isolation techniques and assessment of the stability of exosomes in normal human blood plasma[J]. Proteomics, 2013, 13(22): 3354-3364.
[17] Zheng Q, Bao C, Guo W, et al. Circular RNA profiling reveals an abundant circHIPK3 that regulates cell growth by sponging multiple miRNAs[J]. Nat Commun, 2016, 7: 11215. doi: 10.1038/ncomms11215.
[18] Madhavan B, Yue S, Galli U, et al. Combined evaluation of a panel of protein and miRNA serum-exosome biomarkers for pancreatic cancer diagnosis increases sensitivity and specificity[J]. Int J Cancer, 2015, 136(11): 2616-2627.
[19] Melo SA, Luecke LB, Kahlert C, et al. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer[J]. Nature, 2015, 523(7559): 177-182.
[20] Peinado H, Alec Kovic M, Lavotshkin S, et al. Corrigendum: melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET[J]. Nat Med, 2016, 22(12): 1502.
[21] Logozzi M, Angelini DF, Iessi E, et al. Increased PSA expression on prostate cancer exosomes in in vitro condition and in cancer patients[J]. Cancer Lett, 2017, 403: 318-329. doi: 10.1016/j.canlet.2017.06.036.
[22] Beckham CJ, Olsen J, Yin PN, et al. Bladder cancer exosomes contain EDIL-3/Del1 and facilitate cancer progression[J]. J Urol, 2014, 192(2): 583-592.
[23] Alegre E, Zubiri L, Perez-Gracia JL, et al. Circulating melanoma exosomes as diagnostic and prognosis biomarkers[J]. Clin Chim Acta, 2016, 454: 28-32. doi: 10.1016/j.cca.2015.12.031
[24] Hoshino A, Costa-Silva B, Shen TL, et al. Tumour exosome integrins determine organotropic metastasis[J]. Nature, 2015, 527(7578): 329-335.
[25] Richards KE, Zeleniak AE, Fishel ML, et al. Cancer-associated fibroblast exosomes regulate survival and proliferation of pancreatic cancer cells[J]. Oncogene, 2017, 36(13): 1770-1778.
[26] Rao Q, Zuo B, Lu Z, et al. Tumor-derived exosomes elicit tumor suppression in murine hepatocellular carcinoma models and humans in vitro[J]. Hepatology, 2016, 64(2): 456-472.
[27] Pascucci L, Cocce V, Bonomi A, et al. Paclitaxel is incorporated by mesenchymal stromal cells and released in exosomes that inhibit in vitro tumor growth: a new approach for drug delivery[J]. J Control Release, 2014, 192(28): 262-270.
[28] Djebali S, Davis CA, Merkel A, et al. Landscape of transcription in human cells[J]. Nature, 2012, 489(7414): 101-108.
[29] Yang S, Sun Z, Zhou Q, et al. MicroRNAs, long noncoding RNAs, and circular RNAs: potential tumor biomarkers and targets for colorectal cancer[J]. Physiol Rev, 2018, 10: 2249-2257. doi: 10.2147/CMAR.S166308
[30] Rabinowits G, Gercel-Taylor C, Day JM, et al. Exosomal microRNA: a diagnostic marker for lung cancer[J]. Clin Lung Cancer, 2009, 10(1): 42-46.
[31] Zheng G, Du L, Yang X, et al. Serum microRNA panel as biomarkers for early diagnosis of colorectal adenocarcinoma[J]. Br J Cancer, 2014, 111(10): 1985-1992.
[32] Jiang X, Du L, Wang L, et al. Serum microRNA expression signatures identified from genome-wide microRNA profiling serve as novel noninvasive biomarkers for diagnosis and recurrence of bladder cancer[J].Int J Cancer, 2015, 136(4): 854-862.
[33] Melo SA, Sugimoto H, O'connell JT, et al. Cancer exosomes perform cell-independent microRNA biogenesis and promote tumorigenesis[J]. Cancer Cell, 2014, 26(5): 707-721.
[34] Zhou W, Fong MY, Min Y, et al. Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis[J]. Cancer Cell, 2014, 25(4): 501-515.
[35] Huang X, Yuan T, Liang M, et al. Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer[J]. Eur Urol,2015, 67(1): 33-41.
[36] Han D, Wang M, Ma N, et al. Long noncoding RNAs: novel players in colorectal cancer[J]. Cancer Lett, 2015, 361(1): 13-21.
[37] Lv M, Xu P, Wu Y, et al. LncRNAs as new biomarkers to differentiate triple negative breast cancer from non-triple negative breast cancer[J]. Oncotarget, 2016, 7(11): 13047-13059.
[38] Li H, An J, Wu M, et al. LncRNA HOTAIR promotes human liver cancer stem cell malignant growth through downregulation of SETD2[J]. Oncotarget, 2015, 6(29): 27847-27864.
[39] Du M, Wang W, Jin H, et al. The association analysis of lncRNA HOTAIR genetic variants and gastric cancer risk in a Chinese population[J]. Oncotarget, 2015, 6(31): 31255-31262.
[40] Peter S, Borkowska E, Drayton RM, et al. Identification of differentially expressed long noncoding RNAs in bladder cancer[J]. Clin Cancer Res,2014, 20(20): 5311-5321.
[41] Liang WC, Fu WM, Wong CW, et al. The lncRNA H19 promotes epithelial to mesenchymal transition by functioning as miRNA sponges in colorectal cancer[J]. Oncotarget, 2015, 6(26): 22513-22525.
[42] Zhu J, Liu S, Ye F, et al. Long noncoding RNA MEG3 interacts with p53 protein and regulates partial p53 target genes in hepatoma cells[J]. PLoS One, 2015, 10(10): e0139790. doi: 10.1371/journal.pone.0139790.
[43] Beermann J, Piccoli MT, Viereck J, et al. Non-coding RNAs in development and disease: background, mechanisms, and therapeutic approaches[J]. Physiol Rev, 2016, 96(4): 1297-1325.
[44] Shang X, Li G, Liu H, et al. Comprehensive circular rna profiling reveals that hsa_circ_0005075, a new circular rna biomarker, is involved in hepatocellular crcinoma development[J]. Medicine, 2016, 95(22): e3811. doi: 10.1097/MD.0000000000003811.
[45] Li P, Chen S, Chen H, et al. Using circular RNA as a novel type of biomarker in the screening of gastric cancer[J]. Clin Chim Acta, 2015, 444:132-136. doi: 10.1016/j.cca.2015.02.018.
[46] Wan L, Zhang L, Fan K, et al. Circular RNA-ITCH suppresses lung cancer proliferation via inhibiting the wnt/beta-catenin pathway[J]. Biomed Res Int, 2016, 2016: 1579490. doi: 10.1155/2016/1579490.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed